Birdwatch Note
2024-09-22 02:31:27 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
健常成人なのに死にすぎ?との図は誤解を招く物です。 この試験は24%弱が基礎疾患を有する方です(pdf45p)。 https://www.pmda.go.jp/drugs/2023/P20231122002/780009000_30500AMX00282_A100_3.pdf 60歳以上は17%です(同36P)。 https://www.pmda.go.jp/drugs/2023/P20231122002/780009000_30500AMX00282_A100_3.pdf この試験は下記に組入基準があり、comorbidities、並存疾患を持つ高齢者を組み入れるとの方針を明記しています。 https://www.nature.com/articles/s41467-024-47905-1 また、プラセボ群にもワクチンを接種する前の3か月程で八千人中5人死亡(コロナ死1、上記29p)は、ベトナムの年間死亡率(千人中7人、8千人で3か月で14人程を大きく下回ります) https://data.worldbank.org/indicator/SP.DYN.CDRT.IN?locations=VN またプラセボ群は16名、同期間に死亡(コロナ死は9)であり明確な有効性を示すデータです。
Written by F4D2E4CA66E08B99BDDE8328BBF4C2313B853B3595C8AC38600E463328C72D9D
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1837641351737102770
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1837681082130747773
- noteId - 1837681082130747773
- participantId -
- noteAuthorParticipantId - F4D2E4CA66E08B99BDDE8328BBF4C2313B853B3595C8AC38600E463328C72D9D Participant Details
- createdAtMillis - 1726972287100
- tweetId - 1837641351737102770
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 1
- misleadingManipulatedMedia - 1
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 1
- misleadingUnverifiedClaimAsFact - 1
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- 健常成人なのに死にすぎ?との図は誤解を招く物です。 この試験は24%弱が基礎疾患を有する方です(pdf45p)。 https://www.pmda.go.jp/drugs/2023/P20231122002/780009000_30500AMX00282_A100_3.pdf 60歳以上は17%です(同36P)。 https://www.pmda.go.jp/drugs/2023/P20231122002/780009000_30500AMX00282_A100_3.pdf この試験は下記に組入基準があり、comorbidities、並存疾患を持つ高齢者を組み入れるとの方針を明記しています。 https://www.nature.com/articles/s41467-024-47905-1 また、プラセボ群にもワクチンを接種する前の3か月程で八千人中5人死亡(コロナ死1、上記29p)は、ベトナムの年間死亡率(千人中7人、8千人で3か月で14人程を大きく下回ります) https://data.worldbank.org/indicator/SP.DYN.CDRT.IN?locations=VN またプラセボ群は16名、同期間に死亡(コロナ死は9)であり明確な有効性を示すデータです。
Note Ratings
rated at | rated by | |
2024-09-24 01:21:54 -0500 | Rating Details | |
2024-09-22 23:35:14 -0500 | Rating Details | |
2024-09-22 21:11:10 -0500 | Rating Details | |
2024-09-22 10:36:48 -0500 | Rating Details | |
2024-09-22 10:21:04 -0500 | Rating Details | |
2024-09-22 09:21:17 -0500 | Rating Details | |
2024-09-22 09:02:37 -0500 | Rating Details | |
2024-09-22 08:41:31 -0500 | Rating Details | |
2024-09-22 08:23:53 -0500 | Rating Details | |
2024-09-22 07:43:40 -0500 | Rating Details | |
2024-09-22 07:13:32 -0500 | Rating Details | |
2024-09-22 06:32:13 -0500 | Rating Details | |
2024-09-22 06:28:27 -0500 | Rating Details | |
2024-09-22 06:07:29 -0500 | Rating Details | |
2024-09-22 06:06:34 -0500 | Rating Details | |
2024-09-22 05:55:16 -0500 | Rating Details | |
2024-09-22 05:51:26 -0500 | Rating Details | |
2024-09-22 05:20:52 -0500 | Rating Details | |
2024-09-22 04:50:10 -0500 | Rating Details | |
2024-09-22 04:40:26 -0500 | Rating Details | |
2024-09-22 04:34:34 -0500 | Rating Details | |
2024-09-22 04:03:29 -0500 | Rating Details | |
2024-09-22 02:18:12 -0500 | Rating Details | |
2024-09-22 01:54:11 -0500 | Rating Details | |
2024-09-22 01:53:19 -0500 | Rating Details | |
2024-09-22 01:36:20 -0500 | Rating Details | |
2024-09-22 01:32:51 -0500 | Rating Details | |
2024-09-22 01:08:33 -0500 | Rating Details | |
2024-09-22 00:41:29 -0500 | Rating Details | |
2024-09-22 00:34:08 -0500 | Rating Details | |
2024-09-22 00:31:36 -0500 | Rating Details | |
2024-09-22 00:27:30 -0500 | Rating Details | |
2024-09-22 00:16:04 -0500 | Rating Details | |
2024-09-22 00:15:38 -0500 | Rating Details | |
2024-09-22 00:09:34 -0500 | Rating Details | |
2024-09-21 23:57:41 -0500 | Rating Details | |
2024-09-21 23:45:36 -0500 | Rating Details | |
2024-09-21 23:40:34 -0500 | Rating Details | |
2024-09-21 23:26:33 -0500 | Rating Details | |
2024-09-21 23:23:32 -0500 | Rating Details | |
2024-09-21 23:20:12 -0500 | Rating Details | |
2024-09-21 23:13:30 -0500 | Rating Details | |
2024-09-21 23:12:44 -0500 | Rating Details | |
2024-09-21 23:08:14 -0500 | Rating Details | |
2024-09-21 22:55:18 -0500 | Rating Details | |
2024-09-21 22:45:13 -0500 | Rating Details | |
2024-09-21 22:38:06 -0500 | Rating Details | |
2024-09-21 22:37:57 -0500 | Rating Details | |
2024-09-21 22:33:30 -0500 | Rating Details | |
2024-09-21 22:31:29 -0500 | Rating Details | |
2024-09-21 22:29:56 -0500 | Rating Details | |
2024-09-21 22:25:26 -0500 | Rating Details | |
2024-09-21 22:19:08 -0500 | Rating Details | |
2024-09-21 22:17:55 -0500 | Rating Details | |
2024-09-21 22:14:44 -0500 | Rating Details | |
2024-09-21 22:12:34 -0500 | Rating Details | |
2024-09-21 22:07:19 -0500 | Rating Details | |
2024-09-21 22:05:35 -0500 | Rating Details | |
2024-09-21 22:01:18 -0500 | Rating Details | |
2024-09-21 21:59:41 -0500 | Rating Details | |
2024-09-21 21:56:50 -0500 | Rating Details | |
2024-09-21 21:56:03 -0500 | Rating Details | |
2024-09-21 21:54:18 -0500 | Rating Details | |
2024-09-21 21:53:07 -0500 | Rating Details | |
2024-09-21 21:50:25 -0500 | Rating Details | |
2024-09-21 21:43:27 -0500 | Rating Details | |
2024-09-21 21:40:50 -0500 | Rating Details | |
2024-09-21 21:39:59 -0500 | Rating Details | |
2024-09-21 21:33:21 -0500 | Rating Details | |
2024-10-02 21:36:12 -0500 | Rating Details |